Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Hsieh

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Current Opinion in Lipidology|November 7, 2024
Cholesteryl ester transfer protein inhibition: a pathway to reducing risk of morbidity and promoting longevityMichael H Davidson, Andrew Hsieh, John J P Kastelein
Journal of the American Society for Mass Spectrometry|September 12, 2025
Cysteine Reactivity Profiling Illuminates Monoclonal Antibody Disulfide Bond Reduction Mechanisms in Biopharmaceutical Process IntermediatesTaku Tsukidate, Zhenshu Wang, Andrew Hsieh, et al.
Cognitive Science|June 4, 2011
Perceiving the present and a systematization of illusionsMark A Changizi, Andrew Hsieh, Romi Nijhawan, et al.
JACC. Basic to Translational Science|September 19, 2024
The Imperative to Enhance Cost-Effectiveness for Cardiovascular Therapeutic DevelopmentMichael H Davidson, Andrew Hsieh, Mary R Dicklin, et al.
Expert Review of Cardiovascular Therapy|June 12, 2018
The effect of volanesorsen treatment on the burden associated with familial chylomicronemia syndrome: the results of the ReFOCUS studyMarcello Arca, Andrew Hsieh, Handrean Soran, et al.
Expert Review of Cardiovascular Therapy|March 25, 2017
The burden of familial chylomicronemia syndrome: interim results from the IN-FOCUS studyMichael Davidson, Michael Stevenson, Andrew Hsieh, et al.
Journal of Patient-Reported Outcomes|August 12, 2021
Development of a novel PRO instrument for use in familial chylomicronemia syndromeDavid Davidson, Christina Slota, Montserrat Vera-Llonch, et al.
Expert Review of Cardiovascular Therapy|August 30, 2017
The burden of familial chylomicronemia syndrome from the patients' perspectiveAndres Gelrud, Karren R Williams, Andrew Hsieh, et al.
Current Atherosclerosis Reports|December 22, 2023
Obicetrapib: Reversing the Tide of CETP Inhibitor DisappointmentsJohn J P Kastelein, Andrew Hsieh, Mary R Dicklin, et al.
Drugs in R&D|January 13, 2017
Net Budgetary Impact of Ferric Citrate as a First-Line Phosphate Binder for the Treatment of Hyperphosphatemia: A Markov Microsimulation ModelSteven M Brunelli, Scott P Sibbel, David Van Wyck, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Current Opinion in Lipidology|November 7, 2024
Cholesteryl ester transfer protein inhibition: a pathway to reducing risk of morbidity and promoting longevityMichael H Davidson, Andrew Hsieh, John J P Kastelein
Journal of the American Society for Mass Spectrometry|September 12, 2025
Cysteine Reactivity Profiling Illuminates Monoclonal Antibody Disulfide Bond Reduction Mechanisms in Biopharmaceutical Process IntermediatesTaku Tsukidate, Zhenshu Wang, Andrew Hsieh, et al.
Cognitive Science|June 4, 2011
Perceiving the present and a systematization of illusionsMark A Changizi, Andrew Hsieh, Romi Nijhawan, et al.
JACC. Basic to Translational Science|September 19, 2024
The Imperative to Enhance Cost-Effectiveness for Cardiovascular Therapeutic DevelopmentMichael H Davidson, Andrew Hsieh, Mary R Dicklin, et al.
Expert Review of Cardiovascular Therapy|June 12, 2018
The effect of volanesorsen treatment on the burden associated with familial chylomicronemia syndrome: the results of the ReFOCUS studyMarcello Arca, Andrew Hsieh, Handrean Soran, et al.
Expert Review of Cardiovascular Therapy|March 25, 2017
The burden of familial chylomicronemia syndrome: interim results from the IN-FOCUS studyMichael Davidson, Michael Stevenson, Andrew Hsieh, et al.
Journal of Patient-Reported Outcomes|August 12, 2021
Development of a novel PRO instrument for use in familial chylomicronemia syndromeDavid Davidson, Christina Slota, Montserrat Vera-Llonch, et al.
Expert Review of Cardiovascular Therapy|August 30, 2017
The burden of familial chylomicronemia syndrome from the patients' perspectiveAndres Gelrud, Karren R Williams, Andrew Hsieh, et al.
Current Atherosclerosis Reports|December 22, 2023
Obicetrapib: Reversing the Tide of CETP Inhibitor DisappointmentsJohn J P Kastelein, Andrew Hsieh, Mary R Dicklin, et al.
Drugs in R&D|January 13, 2017
Net Budgetary Impact of Ferric Citrate as a First-Line Phosphate Binder for the Treatment of Hyperphosphatemia: A Markov Microsimulation ModelSteven M Brunelli, Scott P Sibbel, David Van Wyck, et al.
Pageof 4